

CardiNor announces CE marking and launch of new Cardiovascular risk marker: The CardiNor Secretoneurin ELISA test

Oslo, Norway, March 14, 2022: Cardiovascular DX company CardiNor AS today announces that it has achieved CE marking according to IVDD for the CardiNor Secretoneurin ELISA test.

This important new frontline biomarker for cardiovascular disease reflects the biological mechanism triggering arrhythmia. CardiNor has a comprehensive clinical program to further strengthen and widening the clinical documentation of its novel biomarker, and the CardiNor Secretoneurin (SN) test is being trialled in patient selection for cardiac rhythm management using Implantable Cardiac Defibrillator (ICD) devices.

SN is the only biomarker shown to be associated with biological processes linked to cardiomyocyte handling and has been described as the “missing link biomarker” in cardiovascular disease risk assessment. This unique biological function may explain why SN is an independent and strong predictor of mortality in all major patient cohorts tested, including patients with ventricular arrhythmia, acute heart failure, and acute respiratory failure patients with CVD and severe sepsis.

“We are delighted to achieve CE marking on this important new biomarker and are now looking forward to expanding our distribution network globally and to prepare for US market entry. The COVID-19 pandemic has further highlighted the need for improved cardiovascular disease risk markers. The CardiNor Secretoneurin ELISA assay will provide clinicians with a key tool for both more accurate risk prediction and patient management.” commented Dag Christiansen, CEO, CardiNor.

The CardiNor SN assay is based on work by Professor Torbjørn Omland and his research group at Akershus University Hospital in Norway who recently received the prestigious Jebsen award and additional funding to further expand their work on biomarkers linked to sudden cardiac arrest.

More information can be found at: <https://cardinor.com/>.

For further information, please contact:

CardiNor AS

Dag Christiansen, CEO

Email: dag.chr@cardinor.com

Phone: +47-92254855

About CardiNor

CardiNor is a Norwegian Diagnostics company founded in 2015 with the purpose of fighting the Heart Failure (HF) pandemic, by leveraging the patented and exclusive rights to the commercial exploitation of Secretoneurin (SN), a blood-based biomarker that provides prognostic insights for several cardiovascular diseases (CVD). The team is focused on developing scalable cardiac biomarker tests to quantify the levels of SN in human blood, addressing a vast and untapped market potential in CVD patient diagnosis, risk stratification and monitoring.